Search

Search Results
Results 68421 - 68430 of 68869 for Activity
  • The evolution of STEAP1 targeted therapy
    White Paper - 6 Jan 2026
    STEAP1 (Six-transmembrane epithelial antigen of the prostate 1), originally identified in prostate cancer, is a member of the STEAP protein family.
  • Cresemba
    Drug - 30 Dec 2025
    Consumer Medicine Information (CMI) about Cresemba intended for persons living in Australia.
  • Evrysdi
    Drug - 22 Dec 2025
    Consumer Medicine Information (CMI) about Evrysdi intended for persons living in Australia.
  • Actilyse
    Drug - 19 Dec 2025
    Consumer Medicine Information (CMI) about Actilyse intended for persons living in Australia.
  • Ixifi
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Ixifi intended for persons living in Australia.
  • Fonat
    Drug - 18 Dec 2025
    Consumer Medicine Information (CMI) about Fonat intended for persons living in Australia.
  • DBL Bleomycin
    Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about DBL Bleomycin intended for persons living in Australia.
  • Levemir Penfill
    Drug - 15 Dec 2025
    Consumer Medicine Information (CMI) about Levemir Penfill intended for persons living in Australia.
  • Simplifying biologic characterization with label-free binding analysis
    Health - 12 Dec 2025
    Learn how label-free quantitation and binding analysis simplify biologic characterization, reducing assay complexity.
  • Levemir FlexPen
    Drug - 12 Dec 2025
    Consumer Medicine Information (CMI) about Levemir FlexPen intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback